CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID
    2.
    发明申请
    CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID 有权
    3- [5-(2-氟 - 戊基) - [1,2,4]氧杂双环[3-y]] - 苯甲酸的晶体形式

    公开(公告)号:US20110040100A1

    公开(公告)日:2011-02-17

    申请号:US12913213

    申请日:2010-10-27

    IPC分类号: C07D271/06

    CPC分类号: A61K31/4245 C07D271/06

    摘要: The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.

    摘要翻译: 本发明涉及3- [5-(2-氟苯基) - [1,2,4]恶二唑-3-基] - 苯甲酸的结晶形式,包含结晶形式的药物组合物和剂型, 它们用于治疗,预防或控制通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病的结晶形式和方法。

    Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid
    3.
    发明授权
    Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid 有权
    结晶形式的3- [5-(2-氟苯基) - [1,2,4]恶二唑-3-基] - 苯甲酸

    公开(公告)号:US07863456B2

    公开(公告)日:2011-01-04

    申请号:US11904005

    申请日:2007-09-24

    IPC分类号: C07D271/06

    CPC分类号: A61K31/4245 C07D271/06

    摘要: The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.

    摘要翻译: 本发明涉及3- [5-(2-氟苯基) - [1,2,4]恶二唑-3-基] - 苯甲酸的结晶形式,包含结晶形式的药物组合物和剂型, 它们用于治疗,预防或控制通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病的结晶形式和方法。

    Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid
    8.
    发明申请
    Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid 有权
    结晶形式的3- [5-(2-氟苯基) - [1,2,4]恶二唑-3-基] - 苯甲酸

    公开(公告)号:US20080171377A1

    公开(公告)日:2008-07-17

    申请号:US11904005

    申请日:2007-09-24

    IPC分类号: C12N1/00 C07D271/06

    CPC分类号: A61K31/4245 C07D271/06

    摘要: The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.

    摘要翻译: 本发明涉及3- [5-(2-氟苯基) - [1,2,4]恶二唑-3-基] - 苯甲酸的结晶形式,包含结晶形式的药物组合物和剂型, 它们用于治疗,预防或控制通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病的结晶形式和方法。